All Articles About Health Care

BSR Insight Article: BSR Around the World

From helping the world’s largest shipping company develop a sustainability strategy to building a multi-stakeholder coalition to address the challenge of conflict minerals in the Democratic Republic of the Congo, we work with business in all sectors and regions to redefine leadership in sustainable business. Read more →

Posted: June 7, 2011 | Topics: Consumer Products, Financial Services, Food, Beverage & Agriculture, Health Care, Information & Communications Technology, Media & Entertainment, Transportation, Travel & Tourism

Case Study: BSR Membership: A Global Network of Sustainability Leaders

BSR is proud to support and partner with our powerful network of member companies, who share with us a focus on building a just and sustainable world. We work every day to provide our member companies with value based on the insights, expertise, and relationships we’ve built through years of hands-on work in the field.

Posted: June 3, 2011 Topics: Consumer Products, Energy, Financial Services, Food, Beverage & Agriculture, Health Care, Information & Communications Technology, Media & Entertainment, Mining, Transportation, Travel & Tourism

Case Study: Leading Business Action on Conflict Minerals

In the eastern Democratic Republic of the Congo (DRC), where armed conflict has claimed more than 5.4 million lives over the past 15 years, militant groups controlling most of the region’s mines use the trade in tin, tantalum, tungsten, and gold as important sources of funding. At the same time, this trade—which feeds into complex supply chains for products ranging from cell phones and cutting tools to jet engines and jewelry—is an important source of income for a million people in the region.

Posted: June 3, 2011 Topics: Energy, Health Care, Information & Communications Technology, Mining, Reporting & Communications, Stakeholder Relations, Supply Chain, Transportation

BSR Insight Article: New Partnerships to Focus on Bringing Low-Cost Drugs to Africa

Mark Little, Director, Healthcare, Advisory Services

With more Chinese life sciences companies expanding their research and development capabilities, these firms have an opportunity to supply much-needed medicines at a reduced rate for people in the Global South. To date, Chinese companies have focused mainly on domestic markets because of government incentives. Read more →

Posted: May 31, 2011 | Topics: Community Engagement & Development, Economic, Social & Cultural Rights, Health Care

Blog: The Future of Nanotechnology for Pharma

Mark Little, Director, Healthcare, Advisory Services

Nanotechnology has supported breakthrough innovation across many industries yet has been met with mixed stakeholder views. Recently, BSR hosted a member event for pharmaceutical companies to discuss nanotechnology applications in the healthcare sector and to consider the related CSR implications. It was an educational experience to be sure with lectures from two science luminaries: Dr. David Hollinshead, Director Science Policy, AstraZeneca and Mike King, an expert from MATTER—a U.K.-based organization focused on stakeholder engagements surrounding new technology applications and their implications for civil society.   Compared to the most material issues pharmaceutical companies face—access to medicines, product quality, supply chain, ethics in sales and marketing—nanotechnology is often treated as a horizon issue. While there are some stakeholders with questions around nanotechnology, we learned that the objective science behind nanotechnology stands to bring pharmaceutical companies more opportunities than risks.   Nano means “small”—and the simple fact is that smaller particles have larger surface area and are therefore more quickly absorbed into the blood stream. As Dr. David Hollinshead put it, “Nanomedicines are most likely better medicines.” And already, many pharmaceutical companies have begun utilizing nanotechnology to improve drug delivery and targeting. In oncology, for example, nanomedicines are being tested for their ability to reach cell targets that have otherwise eluded more conventional medicines. Yet, the nature of this scientific advancement remains surrounded by “unknown unknowns.” And there is a need for companies—in the pharma sector and beyond—to be proactive in the management and communication of this technology. From MATTER’s “Walking with Stakeholders” project, we know that lack of information is itself a source of distrust among stakeholders. As King put it, “It’s not so much that nano is an issue today, but it’s worth managing and watching closely if only to avoid a situation like that in which Monsanto found itself with GM (genetically modified foods).” So for pharmaceutical companies, the question is not, “Is nano a stakeholder concern?” but rather, “What do we need to learn, and then what do we need to show our stakeholders to gain their trust?”  Read more →

Posted: May 23, 2011 | Topics: Health Care, Stakeholder Relations